Novo Nordisk shares fall on latest trial results for new obesity drug
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of 22.7 per cent of their body weight. That was only marginally ahead of results for Mounjaro, an existing rival treatment made by Eli Lilly.
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type 2 diabetes. However, when the drugs are ...
Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...
Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents ...
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback